IL13RA2 and prostate carcinoma: For this purpose, we first focused on analysing the expression of IL-13Rα2 in prostate cell lines, testing the efficacy of the hybrid lytic peptide (Pep-1-Phor21) in killing prostate cancer cells in vitro and the relationship between the prostate cell lines’ sensitivity to Pep-1-Phor21 and their IL-13Rα2 expression.